Investors & News

Investor Relations

Ascendis Pharma is a clinical stage biopharmaceutical company applying its TransCon technology to develop a pipeline of long-acting prodrug therapies with best-in-class profiles to address large markets with significant unmet medical needs.

Stock Information
ASND (Common Stock)
ExchangeNASDAQ GS (US Dollar)
Change (%) Stock is Down 0.53 (1.42%)
Data as of 12/15/17 4:00 p.m. ET
Refresh quote
Stock chart for: ASND.O.  Currently trading at $36.83 with a 52 week high of $42.00 and a 52 week low of $19.21.
Recent NewsMore >>
Ascendis Pharma A/S Announces Participation in Evercore ISI 2017 Biopharma Catalyst/Deep Dive Conference
Ascendis Pharma A/S Reports Third Quarter 2017 Financial Results
Ascendis Pharma A/S Announces Third Quarter 2017 Financial Results Conference Call on November 16
Upcoming EventsMore >>
There are currently no events scheduled.
Primary IR Contact
Scott T. Smith
Chief Financial Officer
Ascendis Pharma

Data provided by Nasdaq. Minimum 15 minutes delayed.